Patients dosed with Cabaletta’s rese-cel manufactured on Cellares’ Cell Shuttle

Investing.com reports Cabaletta Bio (CABA) shares fell about 1.6% after Q2 2026 results. Net loss was $(0.73) per share, down 30% year over year. Cash was about $225.1M, expected to fund operations only into mid-2027. The update included Phase 1/2 data and a new CMC partner, plus an SEC Form 8-K.

Cabaletta Bio, Inc. (CABA) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 caba-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Cabaletta Bio Reports Second Quarter 2026 Financial Results and Provides Business Update Registrational RESET-Myositis ® clinical data on track to be reported in mid-2027 to support 2H27 BLA submission for rese-cel Juvenile m

Cabaletta Bio (NASDAQ:CABA) reported positive early clinical and translational data from the first four patients in the lowest-dose cohort of preconditioning-free (PC-free) rese-cel, an investigational autologous CAR T therapy for autoimmune diseases, and manufacturing/translational results from the first two autoimmune patients treated using the Cellares Cell Shuttle platform. The company said higher doses may be needed without preconditioning and that 50% showed drug-free responses for six mon

Brookfield Corp. said it can manage financing risks tied to a planned US$500 billion partnership to fund AI chip purchases, alongside Nvidia and other financial institutions. Brookfield CFO Nick Goodman cited risk controls like cash-flow contracts. Brookfield reported Q2 distributable earnings of US$1.4 billion (61 cents/share) and profit of US$703 million (14 cents/share).

Akari Therapeutics reported a Q2 2026 net loss of $4.8M, up from $1.9M a year earlier, and said it ended June 30, 2026 with $7.7M cash. The company raised about $8.6M gross proceeds (about $8.0M net) via private placement and warrant exercises. Akari is advancing AKTX-101 toward a planned mid-2027 Phase 1 start.

Gossamer Bio reported Q2 2026 net income of $16.9M and cash, cash equivalents and marketable securities of $57.0M as of June 30, 2026, citing non-operating gains from debt extinguishment. Revenue from collaborators was $9.2M. The company said it plans to submit an NDA for seralutinib in PAH in Sept 2026 and received FDA Pre-NDA Type B minutes. Shareholders approved a convertible note exchange and a potential reverse stock split.